Effects of recombinant insulin-like growth factor I on insulin secretion and renal function in normal human subjects.

Guler, Hans‐Peter; Schmid, Christoph; Zapf, J.; Froesch, E. R.

doi:10.1073/pnas.86.8.2868

Cited by 298 publications

(206 citation statements)

References 20 publications

Supporting

Mentioning

186

Contrasting

Order By: Relevance

“…Reduced IGF-1 levels may, in turn, partially account for the lower eGFR and increased risk for CKD that were observed in individuals with 1hPG Ն155 mg/dl. In fact, previous evidence indicated that plasma IGF-1 levels are associated with GFR (23), and infusion of recombinant IGF-1 increases GFR in normal individuals (24). There is evidence that IGF-1 enhances both renal blood flow and GFR by stimulating IGF-1 receptors (25).…”

Section: Discussionmentioning

confidence: 95%

One-Hour Postload Plasma Glucose Levels Are Associated with Kidney Dysfunction

Succurro

Arturi

Lugarà

et al. 2010

Clinical Journal of the American Society of Nephrology

View full text Add to dashboard Cite

Background and objectives: A cutoff of 155 mg/dl for 1-hour postload plasma glucose (1hPG) during the oral glucose tolerance test (OGTT) is able to identify patients who are at high risk for type 2 diabetes and vascular atherosclerosis. We aimed to examine whether individuals with 1hPG >155 mg/dl are also at increased risk for chronic kidney disease (CKD).Design, setting, participants, & measurements: Atherosclerosis risk factors, OGTT, and estimated GFR by Chronic Kidney Disease Epidemiology Collaboration equation were analyzed in 1075 white individuals without diabetes.Results: The area under the receiver operating characteristic curve for 1hPG was the highest (0.700) compared with the areas under the receiver operating characteristic curve of 0, 30-minute, and 2-hour glucose concentrations. Individuals with 1hPG >155 mg/dl had a worse cardiometabolic risk profile, exhibiting significantly higher body mass index, BP, triglycerides, and fasting insulin levels and lower HDL, IGF-1 levels, and insulin sensitivity, than individuals with 1hPG <155 mg/dl. Estimated GFR was significantly lower in individuals with 1hPG >155 mg/dl. In a logistic regression model adjusted for age and gender, individuals with 1hPG >155 mg/dl showed an increased risk for CKD compared with individuals with 1hPG <155 mg/dl. When the logistic regression analysis was restricted to individuals who had normal glucose tolerance, those with 1hPG >155 mg/dl showed a higher risk for CKD compared with individuals with 1hPG <155 mg/dl.Conclusions: These data suggest that a cutoff point of 155 mg/dl for the 1hPG during OGTT may be helpful in the identification of individuals who are at increased risk for CKD.

show abstract

Section: Discussionmentioning

confidence: 95%

One-Hour Postload Plasma Glucose Levels Are Associated with Kidney Dysfunction

Succurro

Arturi

Lugarà

et al. 2010

Clinical Journal of the American Society of Nephrology

View full text Add to dashboard Cite

show abstract

“…In particular, a single injection of recombinant human IGF-I is able to lower blood glucose over a 3-hour period by increasing glucose uptake and inhibiting hepatic glucose production (2). At the same time, it is well-known that reduction of intra-abdominal fat improves insulin sensitivity in peripheral tissues.…”

Section: Post-vlcd Correlationsmentioning

confidence: 99%

“…Data concerning IGF-I concentrations in patients with obesity are not unanimous, because they have been reported to be lower, equal, or even higher than in lean, age-matched controls (2,3,5,21).…”

Section: Introductionmentioning

confidence: 99%

Divergent Effects of Short‐Term, Very‐Low‐Calorie Diet on Insulin‐Like Growth Factor‐I and Insulin‐Like Growth Factor Binding Protein‐3 Serum Concentrations in Premenopausal Women with Obesity

et al. 1998

View full text Add to dashboard Cite

DE PERGOLA, GIOVANNI, MAURO ZAMBONI, NICOLA PANNACCIULLI, EMANUELA TURCATO, FRANCESCO GIORGINO, FABIO ARMELLINI, FRANCESCO LOGOLUSO, MARCELLO SCIARAFFIA, OTTAVIO BOSELLO, RICCARDO GIORGINO. Divergent effects of short-term, very-low-calorie diet on insulinlike growth factor-I and insulin-like growth factor binding protein-3 serum concentrations in premenopausal women with obesity. Obes Res. 1998;6:408-415. Objective: Insulin-like growth factor-I (IGF-I) and insulinlike growth factor binding protein-3 (IGFBP-3) serum concentrations provide a good measure of the biological effects of growt~hormone. The aims of the present study were to: (I) investigate the associations of IGF-I and IGFBP-3 with body fat mass and distribution, and (2) evaluate the effects of 3 weeks of very-low-calorie diet (VLCD) (318 kcal/day, with 40 g protein, 35 g carbohydrate, and 2 g fat) on IGF-I and IGFBP-3 serum concentrations. Research Methods and Procedures:The study was performed in 21 nondiabetic premenopausal women with obesity (body mass index >27.0 kg/rrr'; age: ranging from 18 to 48 years). Body fat mass and distribution were measured by computed tomography.

show abstract

“…The anti-insulin monoclonal antibody was from Sigma. The anti-IGF-1 receptor and anti-insulin receptor antibodies were from Santa Cruz Biotechnology; both antibodies were raised against the N-terminal unique sequences (amino acids [1][2][3][4][5][6][7][8][9][10][11][12][13][14][15][16][17][18][19][20] of the corresponding receptor. IGF-1 was from Becton Dickinson or GIBCO͞BRL.…”

Section: Methodsmentioning

confidence: 99%

“…Insulin-like growth factor 1 (IGF-1) is one such example. When infused into normal healthy human subjects at a dose not causing hypoglycemia, IGF-1 can decrease the circulating insulin level (2) and IGF-1 can directly attenuate insulin secretion from isolated primary rat pancreatic ␤ cells (3). Insulin itself has been postulated to exert a negative-feedback control of its own secretion (4,5).…”

mentioning

confidence: 99%

Attenuation of insulin secretion by insulin-like growth factor 1 is mediated through activation of phosphodiesterase 3B

Zhao

Teague

et al. 1997

Proc. Natl. Acad. Sci. U.S.A.

138

115

View full text Add to dashboard Cite

Both insulin and insulin-like growth factor 1 (IGF-1) are known to reduce glucose-dependent insulin secretion from the ␤ cells of pancreatic islets. In this paper we show that the mechanism by which IGF-1 mediates this effect is in large part through activation of a specific cyclic nucleotide phosphodiesterase, phosphodiesterase 3B (PDE3B). More specifically, in both isolated pancreatic islets and insulin-secreting HIT-T15 cells, IGF-1 inhibits insulin secretion that has been increased by glucose and glucagonlike peptide 1 (GLP-1). Moreover, IGF-1 decreases cAMP levels in parallel to the reduction of insulin secretion. Insulin secretion stimulated by cAMP analogs that activate protein kinase A and also are substrates for PDE3B is also inhibited by IGF-1. However, IGF-1 does not inhibit insulin secretion stimulated by nonhydrolyzable cAMP analogs. In addition, selective inhibitors of PDE3B completely block the ability of IGF-1 to inhibit insulin secretion. Finally, PDE3B activity measured in vitro after immunoprecipitation from cells treated with IGF-1 is higher than the activity from control cells. Taken together with the fact that pancreatic ␤ cells express little or no insulin receptor but large amounts of IGF-1 receptor, these data strongly suggest a new regulatory feedback loop model for the control of insulin secretion. In this model, increased insulin secretion in vivo will stimulate IGF-1 synthesis by the liver, and the secreted IGF-1 in turn feedback inhibits insulin secretion from the ␤ cells through an IGF-1 receptormediated pathway. This pathway is likely to be particularly important when levels of both glucose and secretagogues such as GLP-1 are elevated.

show abstract

Effects of recombinant insulin-like growth factor I on insulin secretion and renal function in normal human subjects.

Cited by 298 publications

References 20 publications

One-Hour Postload Plasma Glucose Levels Are Associated with Kidney Dysfunction

One-Hour Postload Plasma Glucose Levels Are Associated with Kidney Dysfunction

Divergent Effects of Short‐Term, Very‐Low‐Calorie Diet on Insulin‐Like Growth Factor‐I and Insulin‐Like Growth Factor Binding Protein‐3 Serum Concentrations in Premenopausal Women with Obesity

Attenuation of insulin secretion by insulin-like growth factor 1 is mediated through activation of phosphodiesterase 3B

Contact Info

Product

Resources

About